Use of the COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) is picking up in the US after some initial challenges getting the antiviral to the right patients quickly, but there is still a lot of work to do on expanding access and educating physicians and patients about the treatment, Pfizer Inc. said during its first quarter sales and earnings call on 3 May.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?